Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
RTI Health Solutions, 3040 East Cornwallis Road, Research Triangle Park, NC 27709, USA.
Per Med. 2023 Mar;20(2):131-142. doi: 10.2217/pme-2022-0050. Epub 2023 Feb 7.
To describe real-world testing patterns for in US patients with advanced/metastatic medullary thyroid cancer and determine consistency of real-world testing practices with national guidelines. The authors performed a retrospective medical record analysis of patients with advanced/metastatic medullary thyroid cancer who initiated systemic therapy between 2013 and 2018. Seventy-five US-based oncologists collected the data using a customized electronic data collection form. A total of 59.6% (121 of 203) of patients underwent testing for , and 37.2% (45 of 121) had a mutation, of which 55.6% were identified as mutation-positive before initial diagnosis. Overall, 90 (44.3%) patients were tested for biomarkers on or after initial diagnosis, with being the most tested (95.6%) biomarker. The authors' findings suggest an opportunity to improve testing rates in accordance with treatment guidelines.
描述美国晚期/转移性甲状腺髓样癌患者中进行 RET 基因检测的真实世界模式，并确定真实世界检测实践与国家指南的一致性。作者对 2013 年至 2018 年间开始系统治疗的晚期/转移性甲状腺髓样癌患者进行了回顾性病历分析。75 名美国肿瘤学家使用定制的电子数据收集表收集数据。共有 59.6%（203 例中的 121 例）的患者接受了 RET 基因检测，其中 37.2%（121 例中的 45 例）存在 RET 基因突变，其中 55.6%在初始诊断前被确定为 RET 基因突变阳性。总体而言，90（44.3%）名患者在初始诊断后或之后进行了生物标志物检测，最常检测的生物标志物是（95.6%）。作者的研究结果表明，有机会根据治疗指南提高检测率。
